Trending...
- Submissions of Short Films & Videos are Needed for the 10th Annual Indigenous Film Retreats - 171
- Boomin Reunion Band Itsy Bitsy Teenie Weenie Yellow Polka Dot Bikini Has 10 Million You Tube Streams - 154
- AdvisorVault's 17a-4 Managed 365 Service: Finally, Guaranteed FINRA Compliance On The Microsoft Cloud
SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc. (NYSE American: CLDI or "Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the issuance of a new patent for the company's SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic. In addition, the company also provided an update on the timing of its anticipated clinical milestones.
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,655,455 titled, "Enhanced systems for cell-mediated oncolytic viral therapy," directed to Calidi's SuperNova platform composed of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus.
"This latest patent granted to Calidi covering meaningful features of our SuperNova platform represents an important milestone as we prepare to advance CLD-201 into the clinic," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. "We are pleased to continue strengthening an already robust intellectual property portfolio, and feel we are well-positioned to capture the potential of our efforts to develop a universal and off-the-shelf SuperNova platform to radically transform the landscape for patients with advanced solid tumors."
The patent covers a composition where cells are incubated with an oncolytic virus for a defined period allowing the expression of at least one immunomodulatory protein or recombinant therapeutic protein encoded by the virus, by virtue of association of the virus, with the carrier cell. Early Calidi research has shown the potential ability of the SuperNova platform to shield the viral payload from the immune system, supporting efficient delivery to tumor sites and effectively potentiating oncolytic viruses' therapeutic efficacy.
More on The Californer
"We see great potential in our SuperNova technology to address the vast unmet need for effective treatments of solid tumor cancers," said Dr. Antonio F. Santidrian, Chief Scientific Officer at Calidi Biotherapeutics. "We look forward to initiating our first-in-human clinical trial of our off-the-shelf and allogeneic therapy in 2024."
In addition, Calidi also provided updates on the timing for certain anticipated clinical milestones for its NeuroNova and SuperNova platforms.
Anticipated Clinical Milestones
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
More on The Californer
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as "anticipates," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predicts," "project," "should," "towards," "would" as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statements contained in this discussion, including but not limited to statements listed in "Anticipated Clinical Milestones," and statements concerning the safety and efficacy of our product candidate CLD-201 are based on Calidi's current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Calidi will be those that it has anticipated. Any forward-looking statements involve a number of risks, uncertainties (some of which are beyond Calidi's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Other risks and uncertainties are set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's Registration Statements filed with the SEC on Form S-4 filed on August 2, 2023, on Form S-1 filed on October 6, 2023 and Form 10-Q filed on November 14, 2023.
Contacts
For Investors:
Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com
For Media:
Gwen Gordon
gwen@gwengordonpr.com
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,655,455 titled, "Enhanced systems for cell-mediated oncolytic viral therapy," directed to Calidi's SuperNova platform composed of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus.
"This latest patent granted to Calidi covering meaningful features of our SuperNova platform represents an important milestone as we prepare to advance CLD-201 into the clinic," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. "We are pleased to continue strengthening an already robust intellectual property portfolio, and feel we are well-positioned to capture the potential of our efforts to develop a universal and off-the-shelf SuperNova platform to radically transform the landscape for patients with advanced solid tumors."
The patent covers a composition where cells are incubated with an oncolytic virus for a defined period allowing the expression of at least one immunomodulatory protein or recombinant therapeutic protein encoded by the virus, by virtue of association of the virus, with the carrier cell. Early Calidi research has shown the potential ability of the SuperNova platform to shield the viral payload from the immune system, supporting efficient delivery to tumor sites and effectively potentiating oncolytic viruses' therapeutic efficacy.
More on The Californer
- Fernanda Rocha Launches New YouTube Fitness Channel, Empowering Busy Moms to Prioritize Their Health
- AI-based Tissue Staining to Detect Amyloid Deposits Without Chemical Stains or Microscopy
- California: Governor Newsom welcomes the largest CHP graduating class in over two years
- California's earthquake warning system notified millions ahead of today's Southern California quake
- Long Beach Airport Seeks Community Votes to Make USA Today's Top 10 List of Small Airports
"We see great potential in our SuperNova technology to address the vast unmet need for effective treatments of solid tumor cancers," said Dr. Antonio F. Santidrian, Chief Scientific Officer at Calidi Biotherapeutics. "We look forward to initiating our first-in-human clinical trial of our off-the-shelf and allogeneic therapy in 2024."
In addition, Calidi also provided updates on the timing for certain anticipated clinical milestones for its NeuroNova and SuperNova platforms.
Anticipated Clinical Milestones
- 1H 2024: First patient dosed in CLD-101 (NeuroNova) Phase 1b/2 trial in collaboration with Northwestern University for newly diagnosed high-grade glioma patients
- 2H 2024: First patient dosed in CLD-201 (SuperNova) Phase 1 trial
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
More on The Californer
- Atlas Elite Entertainment Releases New Single "Forever"
- If You're Reading This, You May Have Too Much Time on Your Hands!
- "Monotheism and Devils" is the theologically dedicated sequel of "Prince of Eurasia" of the Islamic cleric and executive producer Prince Oak Oakleyski
- CII presented 2024 Connie Award to Guenther and Taylor given Lifetime Achievement Award
- Long Beach Seeks Volunteers for 40th Annual California Coastal Cleanup Day, September 21
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as "anticipates," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predicts," "project," "should," "towards," "would" as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statements contained in this discussion, including but not limited to statements listed in "Anticipated Clinical Milestones," and statements concerning the safety and efficacy of our product candidate CLD-201 are based on Calidi's current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Calidi will be those that it has anticipated. Any forward-looking statements involve a number of risks, uncertainties (some of which are beyond Calidi's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Other risks and uncertainties are set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's Registration Statements filed with the SEC on Form S-4 filed on August 2, 2023, on Form S-1 filed on October 6, 2023 and Form 10-Q filed on November 14, 2023.
Contacts
For Investors:
Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com
For Media:
Gwen Gordon
gwen@gwengordonpr.com
Filed Under: Business
0 Comments
Latest on The Californer
- JRK Property Holdings Acquires Apartment Communities in San Francisco and Minneapolis
- Long Beach City Council Adopts Fiscal Year 2025 Budget
- New Book Promises to Revolutionize Mindsets and Transform Professional Success for Latinas
- California: Governor Newsom signs "smash-and-grab" bill to strengthen felony sentences for large-scale theft offenses
- Pylontech US Showcases at RE+ 2024 USA - English APAC - Traditional Chinese USA - English
- Diversified Industrial Acquisition Agreement, Plus Major Contract Award for Large Fleet Trucking Provider: MingZhu Logistics: Stock Symbol: YGMZ
- Parking Management Services of America Reports Year-Over-Year Growth and Raises 2025 Sales Guidance
- Award winning author's science fiction novel THE HUMMINGBIRD WHISPERER is available for pre-order
- Messageware Z-Day Guard v1.5 Expands MDR Security to Azure, Exchange, and Windows Servers
- Carlsbad, California Grandma Ignites a National Movement: How a Child's Simple Act of Acknowledgment is Leading the Way to Heal America's Mental Health Crisis
- Huma Raises $38M to Hyper-scale its Payment Financing (PayFi) Network USA - English USA - Turkish
- Hiconics Unveils Innovative Home Energy Solutions at RE+ 2024, Leading Green Energy Trends in North America USA - English USA - English
- SYM Investors Have Opportunity to Lead Symbotic Inc. Securities Fraud Lawsuit
- California: Governor Newsom proclaims state of emergency in response to Bridge and Airport fires, visits Line Fire Incident Command Post
- Horror Short BABUSHKA From Thorny Devil Productions and Five-Tool Player Embark On Festival Journey
- City of Long Beach to Launch Residential Organics Collection Program
- The Ripple Effect Arts, has launched its latest product, Organic Wild Yam Cream, capitalizing on the company's recent viral success on TikTok
- Prince of Eurasia: Monotheism and Devils — the ultrarare Eurasian theological documentary of executive producer Prince Oak Oakleyski
- Sunmed | Your CBD Store Responds to Governor Newsom's Industry-Killing Hemp Regulation
- Secret Room Events Invite Media and Press to Cover the 2024 Red Carpet Lounge in Honor of Nomin